Table 1. Overview of countries and patients tested.
| Country | Second test | Patients tested | Total discordant | Percentage Determine® + 1 |
|---|---|---|---|---|
| CAR | Unigold® | 4, 329 | 143 (3.3%) | 92% |
| Congo-B | Unigold® | 438 | 26 (5.9%) | 46% |
| DRC | Unigold® | 19, 065 | 119 (0.6%) | 74% |
| Ethiopia | Unigold® | 4, 961 | 363 (7.3%) | 15% |
| Haiti | Unigold® | 2, 006 | 20 (1.0%) | 95% |
| Capillus® | 4, 458 | 54 (1.2%) | 100% | |
| India | Unigold® | 1, 193 | 19 (1.6%) | 58% |
| TriDot® | 4, 266 | 59 (1.4%) | 97% | |
| Ivory Coast | Unigold® | 3, 386 | 125 (3.7%) | 90% |
| Hexagon® | 5, 648 | 334 (5.9%) | 39% | |
| Myanmar | Unigold® | 14, 796 | 331 (2.2%) | 90% |
| Capillus® | 25, 024 | 528 (2.1%) | 73% | |
| Uganda | Unigold® | 6, 056 | 129 (2.1%) | 81% |
| Zimbabwe | First Response® | 7, 782 | 18 (0.2%) | 67% |
| SD Bioline® | 2, 627 | 11 (0.4%) | 73% |
1 Refers to the percentage Determine® test positive amongst the discordant tests.